AR111166A1 - Uso intradialítico de nitrito de sodio - Google Patents
Uso intradialítico de nitrito de sodioInfo
- Publication number
- AR111166A1 AR111166A1 ARP180100529A ARP180100529A AR111166A1 AR 111166 A1 AR111166 A1 AR 111166A1 AR P180100529 A ARP180100529 A AR P180100529A AR P180100529 A ARP180100529 A AR P180100529A AR 111166 A1 AR111166 A1 AR 111166A1
- Authority
- AR
- Argentina
- Prior art keywords
- dialysate
- unenriched
- nitrite
- enriched
- membrane
- Prior art date
Links
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 title abstract 18
- 235000010288 sodium nitrite Nutrition 0.000 title abstract 9
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 abstract 10
- 239000000243 solution Substances 0.000 abstract 9
- 239000012528 membrane Substances 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 8
- 238000000502 dialysis Methods 0.000 abstract 7
- 239000007864 aqueous solution Substances 0.000 abstract 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 4
- 239000008280 blood Substances 0.000 abstract 4
- 210000004369 blood Anatomy 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 238000001631 haemodialysis Methods 0.000 abstract 3
- 230000000322 hemodialysis Effects 0.000 abstract 3
- 206010042434 Sudden death Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos para mantener niveles fisiológicos de nitrito en un sujeto que se somete a hemodiálisis. También métodos para administrar nitrito de sodio aceptable desde el punto de vista farmacéutico a un sujeto que se somete a hemodiálisis. Reivindicación 1: Un método para mantener niveles fisiológicos de nitrito en un sujeto que se somete a hemodiálisis, que comprende poner en contacto intradialíticamente la sangre de dicho sujeto con una membrana dializadora que también está en contacto con un dializado enriquecido con nitrito, en donde una solución acuosa que comprende nitrito de sodio se agrega a un dializado no enriquecido a medida que el dializado no enriquecido fluye desde una máquina de diálisis hasta una membrana dializadora, en donde dicho dializado no enriquecido comprende una mezcla de agua, una solución concentrada de ácido y una solución concentrada de bicarbonato, y en donde dicho dializado enriquecido con nitrito tiene un pH mayor de alrededor de 7,0. Reivindicación 8: El método de acuerdo con la reivindicación 1, en donde dicha solución acuosa que comprende nitrito de sodio comprende no más de alrededor de 3 mg/l de nitrito de sodio. Reivindicación 10: El método de acuerdo con la reivindicación 1, en donde dicha solución acuosa que comprende nitrito de sodio se agrega a dicho dializado no enriquecido a través de una válvula que está unida al tubo de dializado en un lugar anterior a la conexión de dicho tubo al dializador. Reivindicación 20: Un método para prevenir infarto de miocardio en un sujeto que se somete a diálisis, que comprende poner en contacto intradialíticamente la sangre de dicho sujeto con una membrana dializadora que también está en contacto con un dializado enriquecido con nitrito, en donde una solución acuosa que comprende nitrito de sodio se agrega a dicho dializado no enriquecido a medida que el dializado no enriquecido fluye desde una máquina de diálisis hasta una membrana dializadora, en donde dicho dializado no enriquecido comprende una mezcla de agua, una solución concentrada de ácido y una solución concentrada de bicarbonato, y en donde dicho dializado enriquecido con nitrito tiene un pH mayor de alrededor de 7,0. Reivindicación 39: Un método para prevenir muerte súbita de origen cardíaco en un sujeto que se somete a diálisis, que comprende poner en contacto intradialíticamente la sangre de dicho sujeto con una membrana dializadora que también está en contacto con un dializado enriquecido con nitrito, en donde una solución acuosa que comprende nitrito de sodio se agrega a dicho dializado no enriquecido a medida que el dializado no enriquecido fluye desde una máquina de diálisis hasta una membrana dializadora, en donde dicho dializado no enriquecido comprende una mezcla de agua, una solución concentrada de ácido y una solución concentrada de bicarbonato, y en donde dicho dializado enriquecido con nitrito tiene un pH mayor de alrededor de 7,0. Reivindicación 58: Un método para prevenir apoplejía en un sujeto que se somete a diálisis, que comprende poner en contacto intradialíticamente la sangre de dicho sujeto con una membrana dializadora que también está en contacto con un dializado enriquecido con nitrito, en donde una solución acuosa que comprende nitrito de sodio se agrega a dicho dializado no enriquecido a medida que el dializado no enriquecido fluye desde una máquina de diálisis hasta una membrana dializadora, en donde dicho dializado no enriquecido comprende una mezcla de agua, una solución concentrada de ácido y una solución concentrada de bicarbonato, y en donde dicho dializado enriquecido con nitrito tiene un pH mayor de alrededor de 7,0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468857P | 2017-03-08 | 2017-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111166A1 true AR111166A1 (es) | 2019-06-12 |
Family
ID=63445965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100529A AR111166A1 (es) | 2017-03-08 | 2018-03-07 | Uso intradialítico de nitrito de sodio |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US10328099B2 (es) |
| EP (2) | EP3592342B1 (es) |
| JP (2) | JP7314050B2 (es) |
| KR (1) | KR102647803B1 (es) |
| AR (1) | AR111166A1 (es) |
| AU (2) | AU2018231016B2 (es) |
| BR (1) | BR112019018861A2 (es) |
| CA (1) | CA3055105A1 (es) |
| IL (4) | IL301302B2 (es) |
| NZ (1) | NZ756701A (es) |
| PH (1) | PH12019501950A1 (es) |
| TW (3) | TWI835595B (es) |
| WO (1) | WO2018165098A1 (es) |
| ZA (2) | ZA201905679B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165108A1 (en) | 2017-03-08 | 2018-09-13 | Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals | Intradialytic use of sodium thiosulfate |
| IL301302B2 (en) | 2017-03-08 | 2024-09-01 | Hope Medical Entpr Inc Dba Hope Pharmaceuticals | Intradialytic use of sodium nitrite |
| US20220331500A1 (en) * | 2019-07-22 | 2022-10-20 | School Juridical Person The Kitasato Institute | Dialyzer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341151C (en) | 1985-09-10 | 2000-12-05 | Elias Klein | Osmotic agents form peritoneal dialysis |
| US6380163B1 (en) | 1992-12-22 | 2002-04-30 | Baxter International Inc. | Peritoneal dialysis solutions with polypeptides |
| FI98538C (fi) | 1993-10-20 | 1997-07-10 | Enso Gutzeit Oy | Menetelmä natriumhydroksidin valmistamiseksi valkolipeästä |
| US6306836B1 (en) | 1994-01-21 | 2001-10-23 | Baxter International Inc. | Peritoneal dialysis solutions containing maltodextrins and amino acids |
| US6436969B1 (en) | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
| JP4882054B2 (ja) | 2000-09-13 | 2012-02-22 | 独立行政法人科学技術振興機構 | 腹膜透析液およびその調製法 |
| WO2005007173A1 (en) * | 2003-07-09 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Use of nitrite salts for the treatment of cardiovascular conditions |
| US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
| US7547637B2 (en) * | 2005-06-21 | 2009-06-16 | Intel Corporation | Methods for patterning a semiconductor film |
| US20090304600A1 (en) | 2008-06-09 | 2009-12-10 | Anupkumar Shetty | Intradialytic administration of sodium thiosulfate |
| US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| HUE035519T2 (en) | 2009-07-08 | 2018-05-02 | Hope Medical Entpr Inc D B A Hope Pharmaceuticals | Sodium thiosulfate-containing pharmaceutical composition |
| WO2013023217A1 (en) * | 2011-08-11 | 2013-02-14 | Board Of Regents, The University Of Texas System | Method of measuring and monitoring in vivo nitrite levels |
| CA2862483A1 (en) | 2012-01-23 | 2013-08-01 | Santalis Pharmaceuticals Inc. | Sandalwood oil and its uses related to clostridium infections |
| JP5486069B1 (ja) | 2012-11-05 | 2014-05-07 | 旭 酒井 | 透析装置 |
| US20140350097A1 (en) | 2013-05-23 | 2014-11-27 | Medinox,Inc. | Treatment of hypotension associated with hemodialysis |
| JP6183832B2 (ja) | 2013-06-19 | 2017-08-23 | 扶桑薬品工業株式会社 | 酸化ストレス抑制型透析用剤およびその調製方法 |
| IL301302B2 (en) | 2017-03-08 | 2024-09-01 | Hope Medical Entpr Inc Dba Hope Pharmaceuticals | Intradialytic use of sodium nitrite |
-
2018
- 2018-03-06 IL IL301302A patent/IL301302B2/en unknown
- 2018-03-06 KR KR1020197029157A patent/KR102647803B1/ko active IP Right Grant
- 2018-03-06 IL IL312092A patent/IL312092A/en unknown
- 2018-03-06 EP EP18763384.7A patent/EP3592342B1/en active Active
- 2018-03-06 CA CA3055105A patent/CA3055105A1/en active Pending
- 2018-03-06 EP EP24182318.6A patent/EP4406595A2/en active Pending
- 2018-03-06 NZ NZ756701A patent/NZ756701A/en unknown
- 2018-03-06 BR BR112019018861A patent/BR112019018861A2/pt unknown
- 2018-03-06 AU AU2018231016A patent/AU2018231016B2/en active Active
- 2018-03-06 JP JP2019548431A patent/JP7314050B2/ja active Active
- 2018-03-06 WO PCT/US2018/021053 patent/WO2018165098A1/en unknown
- 2018-03-07 TW TW112109906A patent/TWI835595B/zh active
- 2018-03-07 US US15/914,353 patent/US10328099B2/en active Active
- 2018-03-07 TW TW113105276A patent/TW202421096A/zh unknown
- 2018-03-07 TW TW107107745A patent/TWI798203B/zh active
- 2018-03-07 AR ARP180100529A patent/AR111166A1/es unknown
-
2019
- 2019-05-03 US US16/403,428 patent/US10898512B2/en active Active
- 2019-08-23 IL IL268882A patent/IL268882B/en unknown
- 2019-08-23 PH PH12019501950A patent/PH12019501950A1/en unknown
- 2019-08-28 ZA ZA2019/05679A patent/ZA201905679B/en unknown
-
2020
- 2020-11-23 US US17/102,411 patent/US11564938B2/en active Active
-
2021
- 2021-07-07 IL IL284684A patent/IL284684B2/en unknown
-
2022
- 2022-07-29 ZA ZA2022/08504A patent/ZA202208504B/en unknown
-
2023
- 2023-01-03 US US18/092,569 patent/US12011456B2/en active Active
- 2023-07-12 JP JP2023114331A patent/JP7551858B2/ja active Active
-
2024
- 2024-05-08 US US18/658,338 patent/US20240285677A1/en active Pending
- 2024-05-28 AU AU2024203535A patent/AU2024203535A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111166A1 (es) | Uso intradialítico de nitrito de sodio | |
| ES2395369T5 (es) | Soluciones basadas en bicarbonato para terapias de diálisis | |
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| EA201071413A1 (ru) | Способ и композиция для лечения повышения внутриглазного давления и глаукомы | |
| BR112016019309A2 (pt) | aparelho para ultrafiltração de um paciente, e uso de um fluido peritoneal para o tratamento de super-hidratação devido à insuficiência cardíaca congestiva pela ultrafiltração peritoneal | |
| AR070195A1 (es) | Recipiente reutilizable de drenaje de efluentes para dialisis y otras terapias medicas de fluido | |
| CO6592015A2 (es) | Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal | |
| AR123570A1 (es) | Tratamientos para el edema macular diabético y la agudeza visual disminuida | |
| BR112015025358A2 (pt) | gotejador ocular e método para administrar gotas de líquido na superfície do olho | |
| MX2019008489A (es) | Tratamiento que comprende la administracion oral o gastrica de edaravona. | |
| PH12019501971A1 (en) | Intradialytic use of sodium thiosulfate | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| MX2017015664A (es) | Administracion intravenosa de citrulina durante cirugia. | |
| RU2013128357A (ru) | Стабильный готовый к применению инъекционный раствор цетрореликса | |
| PL431139A1 (pl) | Kompozycja farmaceutyczna bimatoprostu i tymololu | |
| AR067047A1 (es) | Formulaciones acuosas de acetaminofen para inyeccion. | |
| AR111313A1 (es) | Composición osmóticamente activa para diálisis | |
| Feriani et al. | Peritoneal dialysis solutions and systems | |
| RU2015133365A (ru) | Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно | |
| RU2366174C1 (ru) | Способ бальзамирования трупа | |
| RU2011132753A (ru) | Способ хирургического лечения многокамерного эхинококкоза печени | |
| EA201491841A1 (ru) | Состав эсмолола для парентерального введения | |
| MX2018001041A (es) | Concentrado que contiene alprostadil. | |
| Miyashita | Fatal hyperkalaemia and ventricular fibrillation: case report | |
| Contou | Toxic epidermal necrolysis: case report |